Dr. Peter Attia

In San Francisco?

In San Francisco?

Okay.

Okay.

And you were doing at this point, oncology unrelated to not necessarily focusing on HIV and AIDS related cancer, breast cancer.

And you were doing at this point, oncology unrelated to not necessarily focusing on HIV and AIDS related cancer, breast cancer.

Is this the Davida Hellman Rosenberg book? Yes. Yeah, yeah, yeah, of course.

Is this the Davida Hellman Rosenberg book? Yes. Yeah, yeah, yeah, of course.

This is unbelievable. So you're sitting in Kentucky practicing garden variety oncology. Talk to me about what that's like. I mean, that's completely orthogonal to what you've been doing for the past couple of years.

This is unbelievable. So you're sitting in Kentucky practicing garden variety oncology. Talk to me about what that's like. I mean, that's completely orthogonal to what you've been doing for the past couple of years.

But did they not understand what you had spent the last couple of years doing prior to being in Kentucky? Did they not know what you had done in Uganda?

But did they not understand what you had spent the last couple of years doing prior to being in Kentucky? Did they not know what you had done in Uganda?

I always have to remind myself, tell people what Taxol is, how it works. Just give them a quick, what is neutropenia? Why would we care?

I always have to remind myself, tell people what Taxol is, how it works. Just give them a quick, what is neutropenia? Why would we care?

And the reason we would give somebody with cancer a microtubule inhibitor is because that prevents cells that are dividing. You can't divide. They need these microtubules when they create new cells, and we want to block that.

And the reason we would give somebody with cancer a microtubule inhibitor is because that prevents cells that are dividing. You can't divide. They need these microtubules when they create new cells, and we want to block that.

It had already been approved.

It had already been approved.

So now you're doing post-marketing surveillance on safety.

So now you're doing post-marketing surveillance on safety.